1. Association of RSV-related hospitalization and non-compliance with Palivizumab among commercially insured infants: a retrospective claims analysis
- Author
-
Laura Becker, Michael Frogel, Dan L. Stewart, Brett Pinsky, Kellie J. Ryan, and Jerry G Seare
- Subjects
Palivizumab ,Male ,Pediatrics ,medicine.medical_specialty ,Multivariate analysis ,viruses ,Respiratory Syncytial Virus Infections ,Antibodies, Monoclonal, Humanized ,Antiviral Agents ,Medication Adherence ,Insurance Claim Review ,Non compliance ,medicine ,Humans ,Dosing ,Retrospective Studies ,Respiratory syncytial viruses ,Proportional hazards model ,business.industry ,Incidence (epidemiology) ,Infant, Newborn ,virus diseases ,Infant ,Retrospective cohort study ,Patient compliance ,respiratory system ,Hospitalization ,Infectious Diseases ,For-Profit Insurance Plans ,Female ,Diagnosis code ,business ,Infants ,medicine.drug ,Research Article - Abstract
Background Palivizumab has been shown to decrease the incidence of hospitalization due to respiratory syncytial virus (RSV) in infants at risk of severe RSV disease. We examined the association between compliance with palivizumab dosing throughout the RSV season and risk of RSV-related hospitalization in clinical practice. Methods Subjects who were born and discharged from the hospital before the RSV season and received ≥1 palivizumab dose during their first RSV season were identified from a large US commercial health insurance database between 01/01/03 and 12/31/09. Subjects were deemed compliant if they received ≥5 palivizumab doses without gaps (>35 days) and their first dose was received by November 30. RSV-related hospitalizations were identified using ICD-9-CM diagnosis codes and examined over 2 observation periods: post-index dose and RSV season. A Cox proportional hazard model was used to evaluate the association between non-compliance and RSV-related hospitalization. Results Of the 5,003 subjects who received palivizumab, 62% were deemed non-compliant. Non-compliant subjects had significantly higher unadjusted rates of RSV-related hospitalizations compared to compliant subjects during both observation periods (post-index: 6.1 vs. 2.8 per 100 infant seasons, p
- Published
- 2013